Theracryf Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TCF.L research report →
Companytheracryf.com
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy.
- CEO
- Huw Jones
- IPO
- 2015
- Employees
- 9
- HQ
- Nether Alderley, GB
Price Chart
Valuation
- Market Cap
- $5.05M
- P/E
- -2.51
- P/S
- 0.00
- P/B
- 1.05
- EV/EBITDA
- -1.67
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -37.30%
- ROIC
- -46.75%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-1,941,000 · 38.13%
- EPS
- $-0.00 · 68.42%
- Op Income
- $-2,124,000
- FCF YoY
- 20.99%
Performance & Tape
- 52W High
- $0.30
- 52W Low
- $0.17
- 50D MA
- $0.22
- 200D MA
- $0.21
- Beta
- 1.40
- Avg Volume
- 6.50M
Get TickerSpark's AI analysis on TCF.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TCF.L Coverage
We haven't published any research on TCF.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TCF.L Report →